Iomab-B
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Iomab-B is a radioimmunotherapy comprised of the monoclonal antibody BC8 coupled with the radioisotope Iodine-131. Iomab-B is designed to deliver targeted payloads to cells that express CD45, a pan-leukemic antigen expressed on white blood cells and stem cells. Once attached to target cells, the radioisotope emits energy that destroys cancer cells and bone marrow, thus conditioning the patient prior to HSCT.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 Iomab-B : Acute myeloid leukemia (AML)
LIST OF FIGURES
7 Figure 1: Iomab-B for acute myeloid leukemia – SWOT analysis
8 Figure 2: Datamonitor Healthcare’s drug assessment summary of Iomab-B for acute myeloid leukemia
9 Figure 3: Datamonitor Healthcare’s drug assessment summary of Iomab-B for acute myeloid leukemia
LIST OF TABLES
5 Table 1: Iomab-B drug profile
6 Table 2: Iomab-B late-phase trials in acute myeloid leukemia
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Ivosidenib 
Sign up to the